{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:44:35Z","timestamp":1789771475276,"version":"4.0.1"},"reference-count":142,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of diverse solid tumors; however, concurrent viral infections significantly influence their efficacy and safety profiles. By driving persistent antigen exposure, inducing T cell exhaustion, and remodeling the immunosuppressive tumor microenvironment (TME), viruses extensively reconfigure tumor immune landscapes, leading to marked heterogeneity in responses to immunotherapy. Emerging evidence indicates that patients infected with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), human papillomavirus (HPV), or Epstein\u2013Barr virus (EBV) who receive ICIs therapy may not only regain antitumor immune function, but in some cases may also be associated with virological responses, immunological changes suggestive of improved viral control. However, the risk of viral reactivation remains a concern, particularly in the context of immune-related adverse events (irAEs) requiring immunosuppressive treatment. This review systematically summarizes the current clinical application of ICIs across different viral infection backgrounds and highlights recent advances in the underlying immunological mechanisms. Furthermore, we propose the potential value of virus-specific immune profiling in guiding individualized treatment strategies and emphasize the need to optimize the integration of ICIs and antiviral therapies from the perspective of systemic immune reprogramming.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1807408","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:07Z","timestamp":1777267627000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection\u2013 immunity\u2013cancer crosstalk"],"prefix":"10.3389","volume":"17","author":[{"given":"Guangying","family":"Wang","sequence":"first","affiliation":[{"name":"Queen Mary School, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyin","family":"Chen","sequence":"additional","affiliation":[{"name":"Queen Mary School, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runda","family":"Zhao","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoqi","family":"Liu","sequence":"additional","affiliation":[{"name":"The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Jiangxi Provincial Key Laboratory of Tumor Biology, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yang","sequence":"additional","affiliation":[{"name":"The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Jiangxi Provincial Key Laboratory of Tumor Biology, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daya","family":"Luo","sequence":"additional","affiliation":[{"name":"The MOE Basic Research and Innovation Center for the Targeted Therapeutics of Solid Tumors, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]},{"name":"Jiangxi Provincial Key Laboratory of Tumor Biology, Nanchang University","place":["Nanchang, China"]},{"name":"Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University","place":["Nanchang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/HEP.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030320","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects","volume":"11","author":"Tang","year":"2022","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2022.200239","article-title":"Small DNA tumor viruses and human cancer: preclinical models of virus infection and disease","volume":"14","author":"Spurgeon","year":"2022","journal-title":"Tumour Virus Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108128","article-title":"Viral infections and the efficacy of PD-(L)1 inhibitors in virus-related cancers: head and neck squamous cell carcinoma and hepatocellular carcinoma","volume":"100","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107553","article-title":"Expression of PD-L1 in EBV-associated Malignancies","volume":"95","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","article-title":"Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"12","author":"Xia","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001006","article-title":"A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative","volume":"81","author":"Qian","year":"2025","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002361","article-title":"Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors","volume":"118","author":"Yibirin","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1530","article-title":"Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study","volume":"73","author":"Rasmussen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.bpobgyn.2017.08.006","article-title":"Epidemiology and burden of HPV-related disease","volume":"47","author":"Serrano","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.28526","article-title":"Overall survival, treatment duration, and rechallenge outcomes with ICI therapy for recurrent or metastatic HNSCC","volume":"7","author":"Sun","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B14","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/s41598-019-49771-0","article-title":"HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102944","article-title":"Comparative efficacy of 20 graft-versus-host disease prophylaxis therapies for patients after hematopoietic stem-cell transplantation: a multiple-treatments network meta-analysis","volume":"150","author":"Lv","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00211","article-title":"Evaluating the addition of clinical and staging data to improve the pricing methodology of the Oncology Care Model","volume":"18","author":"Dreyer","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"key":"B20","article-title":"A phase II randomized study of nivolumab in previously untreated resectable HPV-positive and HPV-negative head and neck squamous cell carcinoma","volume":"27","author":"Ferris","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02203-24","article-title":"The retinoblastoma protein contributes to maintaining the stability of HPV E7 in cervical cancer cells","volume":"99","author":"Gbala","year":"2025","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1042\/CS20050369","article-title":"Molecular biology of human papillomavirus infection and cervical cancer","volume":"110","author":"Doorbar","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-022-02481-4","article-title":"The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors","volume":"41","author":"Tosi","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2017.07.007","article-title":"The HPV E6\/E7 oncogenes: key factors for viral carcinogenesis and therapeutic targets","volume":"26","author":"Hoppe-Seyler","year":"2018","journal-title":"Trends Microbiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","article-title":"Immune landscape of viral- and carcinogen-driven head and neck cancer","volume":"52","author":"Cillo","year":"2020","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12280\/gjfckx.20220376","article-title":"Role of STING signaling pathway in HPV-related Malignant tumors","volume":"50","author":"Zhang","year":"2023","journal-title":"J Int Obstetrics Gynecology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1158\/1538-7445.am2019-3789","article-title":"Abstract 3789: Genomic instability changes acquired by HPV16 E6\/E7 targeting multipolar mitoses aneuploidy: cellular sequelae","volume":"79","author":"McGhee","year":"2019","journal-title":"Cancer Res [Internet]"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103679","article-title":"Immunotherapy for head and neck cancer: present and future","volume":"174","author":"Fasano","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.052","article-title":"Blood-based biomarkers for predicting immunotherapy benefit in lung cancer","volume":"183","author":"Camidge","year":"2020","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1538-7445.am2024-4206","article-title":"Abstract 4206: Regional transcriptomic profiling of the head and neck squamous cell carcinoma tumor microenvironment paired with murine models identify extracellular matrix components that mediate tumor progression and immune suppression","volume":"84","author":"Aleman","year":"2024","journal-title":"Cancer Res [Internet]"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040430","article-title":"STAT1-deficient HPV E6\/E7-associated cancers maintain host immunocompetency against therapeutic intervention","volume":"12","author":"Lim","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1089\/cell.2022.0047","article-title":"The tumor microenvironment reprograms immune cells","volume":"24","author":"Cao","year":"2022","journal-title":"Cell Reprogram"},{"key":"B33","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1038\/s41467-021-23355-x","article-title":"B cell signatures and tertiary lymphoid structures contribute to outcome in head and neck squamous cell carcinoma","volume":"12","author":"Ruffin","year":"2021","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","first-page":"100710","DOI":"10.1016\/j.oor.2024.100710","article-title":"Molecular mechanisms and diagnostic innovations in HPV-associated head and neck squamous cell carcinomas: insights into integration, epigenetic modifications, and biomarker applications","author":"Geetha Shanmugam","year":"2025","journal-title":"Oral Oncol Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275270","article-title":"Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC","volume":"14","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004601","article-title":"Immune correlates of clinical parameters in patients with HPV-associated Malignancies treated with bintrafusp alfa","volume":"10","author":"Tsai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25911","article-title":"Serious immune-related adverse events in patients with head and neck cancer after checkpoint blockade: systematic review","volume":"41","author":"Shah","year":"2019","journal-title":"Head Neck"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0147","article-title":"Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 CheckMate 714 randomized clinical trial","volume":"9","author":"Harrington","year":"2023","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1111061","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: a systematic review and a meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1186\/s12885-025-15059-y","article-title":"Safety and efficacy of toripalimab plus concurrent chemoradiotherapy for locally advanced cervical cancer: a single-arm, phase Ib trial","volume":"25","author":"Jiang","year":"2025","journal-title":"BMC Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12885-025-14733-5","article-title":"Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis","volume":"25","author":"Auch","year":"2025","journal-title":"BMC Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225716","article-title":"Recent research on combination of radiotherapy with targeted therapy or immunotherapy in head and neck squamous cell carcinoma: a review for radiation oncologists","volume":"13","author":"Xing","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s43856-022-00159-8","article-title":"Proteome and phosphoproteome signatures of recurrence for HPV+ head and neck squamous cell carcinoma","volume":"2","author":"Kaneko","year":"2022","journal-title":"Commun Med (Lond)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD-1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2016","journal-title":"Oncoimmunology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2021.03.009","article-title":"Tumor microenvironment in head and neck squamous cell carcinoma: functions and regulatory mechanisms","volume":"507","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B48","article-title":"The immune microenvironment in HPV+ tumors","volume":"20","author":"Faget","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110329","article-title":"The current advances and future directions of PD-1\/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82705","article-title":"Proliferative exhausted CD8+ T cells exacerbate long-lasting anti-tumor effects in human papillomavirus-positive head and neck squamous cell carcinoma","volume":"12","author":"Cheng","year":"2023","journal-title":"Elife"},{"key":"B51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41417-023-00682-3","article-title":"HPV E6\/E7: insights into their regulatory role and mechanism in signaling pathways in HPV-associated tumor","volume":"31","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175668","article-title":"Human papillomavirus-associated tumor extracellular vesicles in HPV+ tumor microenvironments","volume":"12","author":"Gameiro","year":"2023","journal-title":"J Clin Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12967-024-05409-y","article-title":"Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response","volume":"22","author":"Sadeghirad","year":"2024","journal-title":"J Transl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03252-21","article-title":"Development of a spontaneous HPV16 E6\/E7-expressing head and neck squamous cell carcinoma in HLA-A2 transgenic mice","volume":"13","author":"Peng","year":"2022","journal-title":"mBio"},{"key":"B55","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint","year":"2015","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102408","article-title":"4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy","volume":"6","author":"Cha","year":"2025","journal-title":"Cell Rep Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.otc.2025.08.009","article-title":"Novel treatment approaches in recurrent\/metastatic squamous head and neck cancer","volume":"59","author":"Llop","year":"2026","journal-title":"Otolaryngol Clin North Am"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1158\/1538-7445.am2025-3321","article-title":"Abstract 3321: Real-world clinical outcome analyses in head and neck squamous cell carcinoma (HNSCC) to uncover TIGIT biology in patients treated with first-line immune checkpoint inhibitors","volume":"85","author":"Thakur","year":"2025","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ccell.2025.02.026","article-title":"Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122387","article-title":"Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1\/PD-L1 antibodies","volume":"338","author":"Najafi","year":"2024","journal-title":"Life Sci"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596583","article-title":"Advances and challenges in immunotherapy in head and neck cancer","volume":"16","author":"Aboaid","year":"2025","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2350249","article-title":"Comparative analysis of the tumor microbiome, molecular profiles, and immune cell abundances by HPV status in mucosal head and neck cancers and their impact on survival","volume":"25","author":"Upadhyay","year":"2024","journal-title":"Cancer Biol Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/v15030714","article-title":"Epstein-Barr virus history and pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"key":"B66","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein Barr virus: Development of vaccines and immune cell therapy for EBV-associated diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44110390","article-title":"Tumor molecular and microenvironment characteristics in EBV-associated Malignancies as potential therapeutic targets: Focus on gastric cancer","volume":"44","author":"Atri-Schuller","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0178-x","article-title":"Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas","volume":"33","author":"Anastasiadou","year":"2019","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br J Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01863-7","article-title":"Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study","volume":"37","author":"Manos","year":"2023","journal-title":"Leukemia"},{"key":"B73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3892\/ijo.2023.5545","article-title":"Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)","volume":"63","author":"Huang","year":"2023","journal-title":"Int J Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study","volume":"151","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1038\/s41467-023-38407-7","article-title":"Clinical efficacy and biomarker analysis of dual PD-1\/CTLA-4 blockade in recurrent\/metastatic EBV-associated nasopharyngeal carcinoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"key":"B76","doi-asserted-by":"publisher","first-page":"7713","DOI":"10.1038\/s41467-024-52153-4","article-title":"Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","journal-title":"Nat Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-025-01618-6","article-title":"Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy","volume":"28","author":"Kim","year":"2025","journal-title":"Gastric Cancer"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn441530-20240507-00166","article-title":"Zhonghua wei chang wai ke za zhi","volume":"27","author":"Zhu","year":"2024","journal-title":"Zhonghua Wei Chang Wai Ke Za Zhi"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007493","article-title":"Single-cell spatial analysis of tumor immune architecture in diffuse large B-cell lymphoma","volume":"6","author":"Colombo","year":"2022","journal-title":"Blood Adv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2527023","article-title":"Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report","volume":"17","author":"Han","year":"2025","journal-title":"Immunotherapy"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2024-209621","article-title":"Immune checkpoint inhibitor-induced gastrointestinal injury: prevalence of cytomegalovirus, adenovirus and Epstein-Barr virus","volume":"78","author":"Chornenkyy","year":"2025","journal-title":"J Clin Pathol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.21109","article-title":"Cytomegalovirus and Epstein-Barr virus reactivation in steroid-refractory immune checkpoint inhibitor colitis","volume":"19","author":"Sanyour","year":"2025","journal-title":"J Infect Dev Ctries"},{"key":"B86","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","article-title":"Hepatocellular carcinoma: signaling pathways and therapeutic advances","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S307962","article-title":"The mechanisms of HBV-induced hepatocellular carcinoma","volume":"8","author":"Jiang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1159\/000534446","article-title":"Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Du","year":"2023","journal-title":"Liver Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31110532","article-title":"Immunotherapy responses in viral hepatitis-induced HCC: a systematic review and meta-analysis","volume":"31","author":"Anwar","year":"2024","journal-title":"Curr Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02978-7","article-title":"Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial","volume":"132","author":"Shao","year":"2025","journal-title":"Br J Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.immuni.2021.06.013","article-title":"Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma","volume":"54","author":"Cheng","year":"2021","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10824-4","article-title":"Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial","volume":"19","author":"Qin","year":"2025","journal-title":"Hepatol Int"},{"key":"B93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.07.038","article-title":"PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients","volume":"45","author":"Peng","year":"2008","journal-title":"Mol Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i4.105797","article-title":"Drug development for chronic hepatitis B functional cure: Recent progress","volume":"17","author":"Liu","year":"2025","journal-title":"World J Hepatol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1044098","article-title":"Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: a real-life retrospective single-center cohort study","volume":"13","author":"Lasagna","year":"2023","journal-title":"Front Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Med (Baltimore)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2020.08.041","article-title":"Hepatitis B reactivation and immune check point inhibitors","volume":"53","author":"Godbert","year":"2021","journal-title":"Dig Liver Dis"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.21037\/apm-23-250","article-title":"Management of autoimmune and viral hepatitis in immunotherapy: a narrative review","volume":"12","author":"Kuo","year":"2023","journal-title":"Ann Palliat Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112689","article-title":"HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: a multicenter study","volume":"28","author":"Liu","year":"2025","journal-title":"iScience"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00432-022-04133-8","article-title":"Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis","volume":"149","author":"Ding","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09538","article-title":"Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: a retrospective, real-world study","volume":"8","author":"Zhao","year":"2022","journal-title":"Heliyon"},{"key":"B106","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.bulcan.2018.01.018","article-title":"Blocking Tim-3 or\/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma","volume":"105","author":"Liu","year":"2018","journal-title":"Bull Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"31530","DOI":"10.1038\/s41598-024-83145-5","article-title":"Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma","volume":"14","author":"Lin","year":"2024","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1186\/s12885-024-12998-w","article-title":"Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104842","article-title":"Efficacy of systemic therapy for advanced hepatocellular carcinoma based on etiology: a systematic review and network meta-analysis of randomized phase III trials","volume":"213","author":"Wong","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"B110","article-title":"Hepatitis C (HCV) agents","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":""},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13739","article-title":"Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection","volume":"26","author":"Alkrekshi","year":"2021","journal-title":"Oncologist"},{"key":"B112","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection","volume":"145","author":"Pertejo-Fernandez","year":"2020","journal-title":"Lung Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.cgh.2021.06.019","article-title":"Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment","volume":"20","author":"Yoo","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae105","article-title":"Hepatitis B virus reactivation risk associated with immune checkpoint inhibitors in tumor treatment: a retrospective study","volume":"54","author":"Yin","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001072","article-title":"Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma","volume":"8","author":"Lee","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.7150\/jca.77247","article-title":"Hepatitis B virus reactivation in cancer patients undergoing immune checkpoint inhibitors therapy: a systematic review","volume":"13","author":"Zhao","year":"2022","journal-title":"J Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70367","article-title":"Comparative risk of hepatitis B virus reactivation in patients receiving immune checkpoint inhibitors or tyrosine kinase inhibitors for liver cancer","volume":"3","author":"Yiu","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13798","article-title":"Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection","volume":"52","author":"Hagiwara","year":"2022","journal-title":"Hepatol Res"},{"key":"B121","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00432-024-05677-7","article-title":"Risk of HBV reactivation in HCC patients undergoing combination therapy of PD-1 inhibitors and angiogenesis inhibitors in the antiviral era","volume":"150","author":"Wang","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","article-title":"Global epidemiology of hepatocellular carcinoma","volume":"15","author":"Singh","year":"2025","journal-title":"J Clin Exp Hepatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-23-28","article-title":"Management of hepatitis B virus and hepatitis C virus infections in patients with cancer receiving immune checkpoint inhibitors","volume":"7","author":"Mustafayev","year":"2024","journal-title":"J Immunother Precis Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000943","article-title":"Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy","volume":"8","author":"Ziogas","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102011","article-title":"The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B\/C, HIV): a review of the available evidence","volume":"86","author":"Tapia Rico","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32730","article-title":"HIV-1, HAART and cancer: a complex relationship","volume":"146","author":"Shmakova","year":"2020","journal-title":"Int J Cancer"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium","volume":"41","author":"El","year":"2023","journal-title":"J Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009728","article-title":"Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study","volume":"12","author":"Assoumou","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001784","article-title":"Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial","author":"Quan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1270881","article-title":"Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV","volume":"14","author":"Benito","year":"2023","journal-title":"Front Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/nm1482","article-title":"Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction","volume":"12","author":"Trautmann","year":"2006","journal-title":"Nat Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001849","article-title":"Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency","volume":"32","author":"Evans","year":"2018","journal-title":"AIDS"},{"key":"B135","doi-asserted-by":"publisher","first-page":"8495","DOI":"10.1038\/ncomms9495","article-title":"Immunological biomarkers predict HIV-1 viral rebound after treatment interruption","volume":"6","author":"Hurst","year":"2015","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/cells11061015gc","article-title":"Impact of anti PD-1 immunotherapy on HIV reservoir and anti-viral immune responses in people living with HIV and cancer","volume":"11","author":"Baron","year":"2022","journal-title":"Cells"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092227","article-title":"Immune checkpoint inhibitors in people living with HIV\/AIDS: facts and controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2008.07.012","article-title":"HBV and HCV chronic infection: autoimmune manifestations and lymphoproliferation","volume":"8","author":"Zignego","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.001","article-title":"Systemic effects of inflammation on health during chronic HIV infection","volume":"39","author":"Deeks","year":"2013","journal-title":"Immunity"},{"key":"B141","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","article-title":"Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity","volume":"81","author":"Narmada","year":"2024","journal-title":"J Hepatol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24569","article-title":"Organ system view of the hepatic innate immunity in HCV infection","volume":"88","author":"Bang","year":"2016","journal-title":"J Med Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807408\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T05:27:12Z","timestamp":1777267632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807408\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":142,"alternative-id":["10.3389\/fimmu.2026.1807408"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807408","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"1807408"}}